153 related articles for article (PubMed ID: 2574912)
1. Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome.
Bardram L; Stadil F
Scand J Gastroenterol Suppl; 1989; 166():95-100; discussion 111-3. PubMed ID: 2574912
[TBL] [Abstract][Full Text] [Related]
2. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
Metz DC; Strader DB; Orbuch M; Koviack PD; Feigenbaum KM; Jensen RT
Aliment Pharmacol Ther; 1993 Dec; 7(6):597-610. PubMed ID: 8161665
[TBL] [Abstract][Full Text] [Related]
3. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
Maton PN
Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
[TBL] [Abstract][Full Text] [Related]
4. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
Meijer JL; Jansen JB; Lamers CB
Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Maton PN; Gardner JD; Jensen RT
Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.
Maton PN; Vinayek R; Frucht H; McArthur KA; Miller LS; Saeed ZA; Gardner JD; Jensen RT
Gastroenterology; 1989 Oct; 97(4):827-36. PubMed ID: 2777040
[TBL] [Abstract][Full Text] [Related]
7. Present experiences with omeprazole in the Zollinger-Ellison syndrome.
Lamers CB
Scand J Gastroenterol Suppl; 1986; 118():123-8. PubMed ID: 3460167
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.
Delchier JC; Soule JC; Mignon M; Goldfain D; Cortot A; Travers B; Isal JP; Bader JP
Dig Dis Sci; 1986 Jul; 31(7):693-9. PubMed ID: 2873001
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
[TBL] [Abstract][Full Text] [Related]
10. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.
McArthur KE; Collen MJ; Maton PN; Cherner JA; Howard JM; Ciarleglio CA; Cornelius MJ; Jensen RT; Gardner JD
Gastroenterology; 1985 Apr; 88(4):939-44. PubMed ID: 3972233
[TBL] [Abstract][Full Text] [Related]
11. Famotidine: effective treatment of Zollinger-Ellison syndrome.
Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
[TBL] [Abstract][Full Text] [Related]
13. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
[TBL] [Abstract][Full Text] [Related]
14. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
Clissold SP; Campoli-Richards DM
Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
[TBL] [Abstract][Full Text] [Related]
15. Famotidine in the therapy of gastric hypersecretory states.
Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients.
Corleto V; Annibale B; D'Ambra G; Saggioro A; Ferrua B; Cassetta MR; Delle Fave G
Aliment Pharmacol Ther; 1993 Apr; 7(2):167-73. PubMed ID: 8485270
[TBL] [Abstract][Full Text] [Related]
17. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
[TBL] [Abstract][Full Text] [Related]
18. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy.
Stewart CA; Termanini B; Sutliff VE; Serrano J; Yu F; Gibril F; Jensen RT
Aliment Pharmacol Ther; 1998 Jan; 12(1):83-98. PubMed ID: 9692706
[TBL] [Abstract][Full Text] [Related]
19. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
[TBL] [Abstract][Full Text] [Related]
20. Review article: the management of Zollinger-Ellison syndrome.
Maton PN
Aliment Pharmacol Ther; 1993 Oct; 7(5):467-75. PubMed ID: 7904187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
